The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
 
Josep M Llovet
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celsion; Eisai; Exelixis; Glycotest; Incyte; Lilly
Research Funding - Bayer Schering Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - Bayer
 
Masatoshi Kudo
Honoraria - Abbvie; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; MSD; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Peter R. Galle
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; Sillajen; Sirtex Medical
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Lilly
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Shuichi Kaneko
Stock and Other Ownership Interests - PeptiDream
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Kowa; Lilly; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Kowa; Lilly; MSD
Research Funding - Bayer; Bristol-Myers Squibb; Eisai; MSD
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Tarveda Therapeutics
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai (Inst)
 
Erluo Chen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Leonid Dubrovsky
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)